{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:12:44Z","timestamp":1793621564474,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid disorders (TD) is a common complication of pegylated-interferon alpha (Peg-IFN\u03b1) therapy. Few studies have investigated the relationship between TD and the efficacy of interferon therapy for chronic hepatitis B (CHB). Therefore, we analyzed the clinical characteristics of TD in patients with CHB treated with Peg-IFN\u03b1, and evaluated the correlation between TD and Peg-IFN\u03b1 treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, the clinical data of 146 patients with CHB receiving Peg-IFN\u03b1 therapy were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the course of Peg-IFN\u03b1 therapy, positive conversion of thyroid autoantibodies and TD occurred in 7.3% (85\/1158) and 8.8% (105\/1187) patients, respectively, and was diagnosed more often in women. The most common thyroid disorder was hyperthyroidism (53.3%), followed by subclinical hypothyroidism (34.3%). We found that thyroid function returned to normal in 78.7% of patients with CHB, and thyroid antibody levels returned to the negative range in approximately 50% of patients after interferon treatment cessation. Only 25% of patients with clinical TD required treatment. Compared with patients with hypothyroidism\/subclinical hypothyroidism, patients with hyperthyroidism\/subclinical hyperthyroidism showed greater reduction and seroclearance of hepatitis B surface antigen (HBsAg) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TD are not an absolute contraindication for interferon therapy; however, patients should be monitored closely during interferon therapy. In pursuit of functional cure, a balance between efficacy and safety must be achieved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-023-01371-w","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T06:02:45Z","timestamp":1684735365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha"],"prefix":"10.1186","volume":"23","author":[{"given":"Yisi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-4540","authenticated-orcid":false,"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053\u201363.","journal-title":"Lancet"},{"key":"1371_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","volume":"135","author":"MF Yuen","year":"2008","unstructured":"Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192\u20139.","journal-title":"Gastroenterology"},{"key":"1371_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"issue":"67","key":"1371_CR4","first-page":"370","volume":"2017","author":"EASL","year":"2017","unstructured":"EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u201398.","journal-title":"J Hepatol"},{"key":"1371_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u201332.","journal-title":"Gut"},{"key":"1371_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg loss with peg-interferon Alfa-2a in Hepatitis B patients with partial response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018;6:25\u201334.","journal-title":"J Clin Transl Hepatol"},{"key":"1371_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","volume":"66","author":"Z Cao","year":"2017","unstructured":"Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66:1058\u201366.","journal-title":"Hepatology"},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1136\/bmj.332.7548.1013","volume":"332","author":"K Patel","year":"2006","unstructured":"Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006;332:1013\u20137.","journal-title":"BMJ"},{"key":"1371_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.21146","volume":"43","author":"JC Mandac","year":"2006","unstructured":"Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661\u201372.","journal-title":"Hepatology"},{"key":"1371_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6823-11-10","volume":"11","author":"HA Tran","year":"2011","unstructured":"Tran HA, Jones TL, Gibson R, Reeves GE. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: a nested case control study. BMC Endocr Disord. 2011;11:10.","journal-title":"BMC Endocr Disord"},{"key":"1371_CR11","unstructured":"JL Hou lai W. The guideline of prevention and treatment for chronic hepatitis B: a, 2015 update Zhonghua Gan Zang Bing Za Zhi 2015 23 888 905."},{"key":"1371_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343\u2013421.","journal-title":"Thyroid"},{"key":"1371_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1517\/14740338.2014.921156","volume":"13","author":"D Kozielewicz","year":"2014","unstructured":"Kozielewicz D, Zale\u015bna A, Dybowska D. Can pegylated interferon \u03b1 2a cause development of thyroid disorders in patients with chronic hepatitis B? Expert Opin Drug Saf. 2014;13:1009\u201314.","journal-title":"Expert Opin Drug Saf"},{"key":"1371_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.beem.2009.07.004","volume":"23","author":"Y Tomer","year":"2009","unstructured":"Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab. 2009;23:703\u201312.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1371_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/105072503322238809","volume":"13","author":"MF Prummel","year":"2003","unstructured":"Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547\u201351.","journal-title":"Thyroid"},{"key":"1371_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/thy.1997.7.891","volume":"7","author":"LK Koh","year":"1997","unstructured":"Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature\u00a0 Thyroid. 1997;7:891\u20136.","journal-title":"Thyroid"},{"key":"1371_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2796.2002.00974.x","volume":"251","author":"O Dalgard","year":"2002","unstructured":"Dalgard O, Bj\u00f8ro K, Hellum K, Myrvang B, Bj\u00f8ro T, Haug E, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251:400\u20136.","journal-title":"J Intern Med"},{"key":"1371_CR18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0168-8278(99)80131-7","volume":"30","author":"S Kakizaki","year":"1999","unstructured":"Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol. 1999;30:794\u2013800.","journal-title":"J Hepatol"},{"key":"1371_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1749-6632.2009.05138.x","volume":"1183","author":"YC Kong","year":"2010","unstructured":"Kong YC, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci. 2010;1183:222\u201336.","journal-title":"Ann N Y Acad Sci"},{"key":"1371_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1210\/jc.2004-1173","volume":"90","author":"N Caraccio","year":"2005","unstructured":"Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium\/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab. 2005;90:1156\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"1371_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","volume":"25","author":"T Okanoue","year":"1996","unstructured":"Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283\u201391.","journal-title":"J Hepatol"},{"key":"1371_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/hep.510260127","volume":"26","author":"M Deutsch","year":"1997","unstructured":"Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997;26:206\u201310.","journal-title":"Hepatology"},{"key":"1371_CR23","doi-asserted-by":"publisher","first-page":"300060521102513","DOI":"10.1177\/03000605211025139","volume":"49","author":"W Luo","year":"2021","unstructured":"Luo W, Wu S, Chen H, Wu Y, Peng J. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with \u03b1-interferon. J Int Med Res. 2021;49:3000605211025139.","journal-title":"J Int Med Res"},{"key":"1371_CR24","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1001\/archinte.164.21.2371","volume":"164","author":"EJ Bini","year":"2004","unstructured":"Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004;164:2371\u20136.","journal-title":"Arch Intern Med"},{"key":"1371_CR25","first-page":"62","volume":"79","author":"HY Lin","year":"1994","unstructured":"Lin HY, Thacore HR, Davis PJ, Davis FB. Thyroid hormone potentiates the antiviral action of interferon-gamma in cultured human cells. J Clin Endocrinol Metab. 1994;79:62\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1371_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1530\/EJE-06-0735","volume":"156","author":"M Rotondi","year":"2007","unstructured":"Rotondi M, Minelli R, Magri F, Leporati P, Romagnani P, Baroni MC, et al. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. Eur J Endocrinol. 2007;156:409\u201314.","journal-title":"Eur J Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01371-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01371-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01371-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T06:03:26Z","timestamp":1684735406000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01371-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01371-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2606042\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in accordance with the Declaration of Helsinki, and approved by the research ethics committee of the Beijing Youan Hospital, Capital Medical University, China ([2022]046). The requirement for informed consent was waived due to the observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}